A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial.
2018 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial.
Seufferlein, T.; Lausser, L.; Stein, A. ; Prager, G. W.; Kasper, S.; Niedermeier, M. & Müller, L. et al. (2018)
Journal of Clinical Oncology, 36(15_suppl) pp. e15545-e15545. DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.e15545
Documents & Media
Details
- Authors
- Seufferlein, Thomas; Lausser, Ludwig; Stein, Alexander ; Prager, Gerald W.; Kasper, Stefan; Niedermeier, Michael; Müller, Lothar; Kubicka, Stefan; Koenig, Alexander ; Buechner-Steudel, Petra; Wille, Kai; Perkhofer, Lukas; Hann, Alexander; Berger, Andreas Wolfgang; Arnold, Dirk; Kestler, Hans; Ettrich, Thomas Jens
- Issue Date
- 2018
- Journal
- Journal of Clinical Oncology
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
